## ICMJE DISCLOSURE FORM

Date:	07/10/2022		
Your Name:	MARÍA JOSÉ ARIZA_		
Manuscript Title:	Familial Chylomicro	nemia Syndrome: a diagnosis challenge	
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_XNone	
4	Consulting fees	None	
		Akcea	Personal payment for consulting services

5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events	EAS	Personal payment for a presentation from the European Atherosclerosis Society
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	X_None	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	X_None	

## Please summarize the above conflict of interest in the following box:

I received once personal payments for consulting services from Akcea in 2020 and for a presentation in 2021 from the European Atherosclerosis Society.

Please place an "X" next to the following statement to indicate your agreement:

\_\_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ARIZA CORBO MARIA JOSE -51912695Q Firmado digitalmente por ARIZA CORBO MARIA JOSE - 51912695Q Fecha: 2022.10.07 09:09:02 +02'00'

## ICMJE DISCLOSURE FORM

Date:		
Your Name: PEDRO VALDIVIELSO		
Manuscript Title: Familial Chylomicronemia Syndrome in children: a diagnosis challenge		
Manuscript number (if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
2	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: past SanofiNone	36 months Both
4	Consulting fees	Sanofi, Amgen, Amarin, Akcea, Daiichi-Sankyo	Personal payments

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Sanofi, Amgen, Amarin, Akcea, Daiichi-Sankyo, Servier	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Daiichi-Sankyo, Servier, Sanofi, Amgen, Sobi, PTC	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Sanofi, Amgen, Amarin, Akcea, Daiichi-Sankyo	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

## Please summarize the above conflict of interest in the following box:

I received honoraria as speaker from Sanofi, Amgen, Amarin, Akcea, Daiichi-Sankyo, Servier, as advisor from Sanofi, Amgen, Amarin, Akcea, Daiichi-Sankyo, a grant from Sanofi and support to travel from Daiichi-Sankyo, Servier, Sanofi, Amgen, Sobi, PTC.

Please place an "X" next to the following statement to indicate your agreement:

\_XX\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.